Literature DB >> 4173333

In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.

J M Dickinson, D A Mitchison.   

Abstract

Mesh:

Substances:

Year:  1968        PMID: 4173333     DOI: 10.1016/s0041-3879(68)80051-0

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


× No keyword cloud information.
  8 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

2.  Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.

Authors:  Lucila Garcia-Contreras; Danielle J Padilla-Carlin; Jean Sung; Jarod VerBerkmoes; Pavan Muttil; Katharina Elbert; Charles Peloquin; David Edwards; Anthony Hickey
Journal:  J Pharm Sci       Date:  2016-11-11       Impact factor: 3.534

3.  Intermittent chemotherapy in pulmonary tuberculosis--current aspects.

Authors:  M Zierski
Journal:  Pneumonologie       Date:  1972

4.  Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.

Authors:  Amy Sarah Ginsburg; Jin Lee; Samuel C Woolwine; Jacques H Grosset; Fayez M Hamzeh; William R Bishai
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Postantibiotic effects of antituberculosis agents alone and in combination.

Authors:  C Y Chan; C Au-Yeang; W W Yew; M Hui; A F Cheng
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.

Authors:  Kamunkhwala Gausi; Elisa H Ignatius; Xin Sun; Soyeon Kim; Laura Moran; Lubbe Wiesner; Florian von Groote-Bidlingmaier; Richard Hafner; Kathleen Donahue; Naadira Vanker; Susan L Rosenkranz; Susan Swindells; Andreas H Diacon; Eric L Nuermberger; Kelly E Dooley; Paolo Denti
Journal:  Am J Respir Crit Care Med       Date:  2021-12-01       Impact factor: 21.405

7.  In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.

Authors:  Chiu-Yeung Chan; Carrie Au-Yeang; Wing-Wai Yew; Chi-Chiu Leung; Augustine F B Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

8.  Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.

Authors:  Mohideen S Jawahar; Vaithilingam V Banurekha; Chinnampedu N Paramasivan; Fathima Rahman; Rajeswari Ramachandran; Perumal Venkatesan; Rani Balasubramanian; Nagamiah Selvakumar; Chinnaiyan Ponnuraja; Allaudeen S Iliayas; Navaneethapandian P Gangadevi; Balambal Raman; Dhanaraj Baskaran; Santhanakrishnan R Kumar; Marimuthu M Kumar; Victor Mohan; Sudha Ganapathy; Vanaja Kumar; Geetha Shanmugam; Niruparani Charles; Murugesan R Sakthivel; Kannivelu Jagannath; Chockalingam Chandrasekar; Ramavaram T Parthasarathy; Paranji R Narayanan
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.